A 4-month-old infant weighing 6 kg is admitted to the pediatric intensive care unit for treatment of gram-negative sepsis. The attending physician orders intravenous gentamicin at 2.5 mg/kg per dose. A decimal point error occurs during the manual calculation and compounding process in the central pharmacy, resulting in a syringe containing 150 mg of gentamicin instead of the intended 15 mg. The syringe is subsequently labeled as "Gentamicin 15 mg".
At the bedside, the nurse bypasses the barcode medication administration (BCMA) system because the scanner battery is depleted. The nurse assumes the physical volume is appropriate and administers the entire syringe. The infant survives but develops irreversible sensorineural hearing loss.
A multidisciplinary Root Cause Analysis (RCA) is convened. The committee identifies multiple vulnerabilities, including manual calculation requirements, inadequate pharmacy staffing, and faulty BCMA equipment on the ward.
When designing the corrective action plan, the committee must prioritize interventions based on the hierarchy of safety controls. Which of the following proposed interventions represents the most reliable, highest-leverage system change to prevent recurrence of this specific type of error?
- AImplementing a mandatory policy requiring two clinical pharmacists to independently calculate and verify all pediatric weight-based medication doses prior to compounding
- Procuring commercially prepared, standardized unit-dose syringes of high-risk pediatric medications to eliminate the need for manual compounding in the hospital pharmacyCevap
- CConfiguring a hard-stop within the electronic health record that prevents nurses from bypassing the BCMA system without an explicit override from the attending physician
- DInitiating a prospective Failure Mode and Effects Analysis (FMEA) for the pediatric medication administration pathway to map process vulnerabilities
- EMandating annual simulation-based competency assessments for all pediatric nurses on recognizing appropriate weight-based medication volumes